ClinVar Miner

Submissions for variant NM_004006.3(DMD):c.5074A>G (p.Thr1692Ala)

gnomAD frequency: 0.00001  dbSNP: rs367674503
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001051005 SCV001215138 uncertain significance Duchenne muscular dystrophy 2019-01-29 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with DMD-related conditions. This variant is present in population databases (rs367674503, ExAC 0.002%). This sequence change replaces threonine with alanine at codon 1692 of the DMD protein (p.Thr1692Ala). The threonine residue is highly conserved and there is a small physicochemical difference between threonine and alanine.
Ambry Genetics RCV003380819 SCV004097127 uncertain significance Cardiovascular phenotype 2023-07-05 criteria provided, single submitter clinical testing The p.T1692A variant (also known as c.5074A>G), located in coding exon 36 of the DMD gene, results from an A to G substitution at nucleotide position 5074. The threonine at codon 1692 is replaced by alanine, an amino acid with similar properties. Based on data from gnomAD, the G allele has an overall frequency of 0.0005%% (1/182928) total alleles studied, with no hemizygotes observed. The highest observed frequency was 0.0012% (1/81505) of European (non-Finnish) alleles. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Natera, Inc. RCV001832469 SCV002093542 uncertain significance Becker muscular dystrophy; Duchenne muscular dystrophy; Cardiomyopathy; Dystrophin deficiency 2021-06-24 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.